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ABSTRACT
Neutralizing antibodies (NAbs) targeting glycoprotein E2 are important for the control of hepatitis C virus (HCV) infection. One
conserved antigenic site (amino acids 412 to 423) is disordered in the reported E2 structure, but a synthetic peptide mimicking
this site forms a-hairpin in complex with three independent NAbs. Our structure of the same peptide in complex with NAb
3/11 demonstrates a strikingly different extended conformation.We also show that residues 412 to 423 are essential for virus
entry but not for E2 folding. Together with the neutralizing capacity of the 3/11 Fab fragment, this indicates an unexpected
structural flexibility within this epitope. NAbs 3/11 and AP33 (recognizing the extended and -hairpin conformations, respec-
tively) display similar neutralizing activities despite converse binding kinetics. Our results suggest that HCV utilizes conforma-
tional flexibility as an immune evasion strategy, contributing to the limited immunogenicity of this epitope in patients, similar
to the conformational flexibility described for other enveloped and nonenveloped viruses.
IMPORTANCE
Approximately 180 million people worldwide are infected with hepatitis C virus (HCV), and neutralizing antibodies play an im-
portant role in controlling the replication of this major human pathogen.We show here that one of the most conserved antigenic
sites within the major glycoprotein E2 (amino acids 412 to 423), which is disordered in the recently reported crystal structure of
an E2 core fragment, can adopt different conformations in the context of the infectious virus particle. Recombinant Fab frag-
ments recognizing different conformations of this antigenic site have similar neutralization activities in spite of converse kinetic
binding parameters. Of note, an antibody response targeting this antigenic region is less frequent than those targeting other
more immunogenic regions in E2. Our results suggest that the observed conformational flexibility in this conserved antigenic
region contributes to the evasion of the humoral host immune response, facilitating chronicity and the viral spread of HCV
within an infected individual.
An estimated 180 million people worldwide are infected byhepatitis C virus (HCV), and themajority of infected patients
(70 to 80%) develop chronic infection that leads to progressive
liver disease (1). Major advances in HCV therapy during the last
decade resulted in combination therapies consisting of direct-act-
ing antivirals (DAAs) with sustained virological response rates of
90% (reviewed in reference 2). Nevertheless, the lack of avail-
ability of this HCV therapy in developing countries illustrates the
urgent need to design a safe and efficient HCV vaccine, a process
that is hampered by our limited understanding of the key epitopes
inducing a protective neutralizing immune response.
The majority of neutralizing antibodies (NAbs) identified to
date target the major envelope glycoprotein E2 (reviewed in ref-
erence 3), which binds the cellular receptors CD81 and scavenger
receptor BI (SR-BI) (4, 5). The glycoprotein contains hypervari-
able regions (HVRs), termedHVR1, HVR2, and igVR (intergeno-
typic variable region) (6, 7), the deletion of which does not affect
the overall glycoprotein conformation. The structurally flexible
HVR1 located at the N terminus of E2 (8) is dispensable for virus
infectivity in chimpanzees (9). Recent structural studies have
shown that HCV E2 has a core fragment with an Ig superfamily
fold flanked by a front layer and a back layer containing -sheets,
random coils, and short -helices (10, 11). Of note, both struc-
tures were obtained by using an E2 fragment lacking HVR1; thus,
an interaction of HVR1 with the E2 core cannot be excluded.
The neutralizing antibody AR3C binds to a large part of the
front layer (amino acids [aa] 426 to 446) and residues within the
CD81 binding loop (aa 528 to 531). Further insights into the rec-
ognition of E2 neutralizing epitopes came from structural studies
that cocrystallized Fab fragments derived from anti-E2 NAbs rec-
ognizing two regions comprising residues 430 to 446 and 412 to
423, respectively, in complex with their respective epitope pep-
tides (12–18). In these complexes, the peptide comprising aa 430
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to 446 adopts a short -helical conformation, with extended seg-
ments in either direction (12, 16), and was proposed to adopt two
discrete conformations in the context of the viral particle based on
these peptide structures (11, 13). The segment comprising aa 412
to 423 adopts a -hairpin in complex with three independent
broadly neutralizing antibodies (HCV1, AP33, and Hu5B3.v3),
suggesting a flexible flap-like structure (14, 15, 17, 18). The anti-
genic site spanning aa 412 to 423 contains highly conserved
epitopes targeted by monoclonal antibodies (MAbs) neutralizing
HCV strains of all major genotypes (19–23) and is positioned
downstream of HVR1. All described epitopes include a trypto-
phan residue at position 420 that plays a critical role in CD81
recognition (24); nonetheless, a surprisingly weak immune re-
sponse against this antigenic site was reported for infected patients
(22, 25).
Here we report the crystal structure of the epitope comprising
aa 412 to 423 in complex with the neutralizing anti-HCV E2 an-
tibody 3/11, unexpectedly revealing an extended peptide confor-
mation that is strikingly different from the previously reported
-hairpin. We demonstrate that the segment spanning aa 412 to
423 is not required for the native overall fold of a soluble E2 (sE2)
ectodomain but is essential for the infectivity of HCV pseudopar-
ticles (HCVpp) and cell culture-derived HCV (HCVcc). A com-
parative functional analysis of Fab fragments derived from NAbs
3/11 and AP33, exemplary for NAbs recognizing the -hairpin,
reveals similar neutralization activities for both NAbs and Fab
fragments in spite of strikingly different binding kinetics. In com-
bination with the neutralizing activity of MAb 3/11, our results
illustrate the structural flexibility of this region within HCV E2
and provide novel insights into the recognition of conserved neu-
tralizing epitopes, with implications for vaccine design.
MATERIALS AND METHODS
Production and purification of recombinant Fabs and glycoproteins.
Synthetic genes of the Fab coding regions of MAbs 3/11 and AP33 were
cloned into aDrosophila melanogaster S2 Fab expression vector described
previously (26). The HCV E2 full-length ectodomain (sE2), the ectodo-
main lacking hypervariable region 1 (sE2 HVR1) (amino acids 412 to
715 of the HCV polyprotein), and the ectodomain lacking the N-terminal
42 residues (sE2426–717) from strain UKN2B2.8 (GenBank accession
number AY734983) were expressed in Drosophila S2 cells as previously
described (27, 28). Briefly,Drosophila S2 cells were transfected as reported
previously (63), amplified, and induced with 4 M CdCl2 at a density of
7  106 cells/ml for 8 days for large-scale production. Proteins were
purified from the supernatant by affinity chromatography using a Strep-
Tactin Superflow column followed by size exclusion chromatography
(SEC) using a Superdex200 column. Pure monomeric proteins were con-
centrated to20 mg/ml.
Neutralizing capacity of recombinant Fab fragments and infectivity
of HCVcc and HCVpp aa384–425 deletion mutants. HCVcc of H77/
JFH-1 and J6/JFH-1 were produced as previously described (29). A mu-
tant HCV J6/JFH1 clone lacking HVR1 (aa 384 to 410) was generated by
using plasmid pFL-J6/JFH1 as the template (29) and the Q5 site-directed
mutagenesis kit (NEB) (primers are available upon request). Huh7.5 cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)–10%
fetal calf serum (FCS) and harvested at 24, 48, and 72 h following trans-
fections. NS5A expression, as an indirect indicator for replication/trans-
lation, was assessed by immunostaining of electroporated cells usingMAb
9E10. Supernatants were then used to infect naive cells, and infectivity was
assessed by NS5A immunostaining after 48 h.
Neutralization assays were performed by mixing 100 focus-forming
units (FFU) of HCVcc in the absence or presence of the indicated concen-
trations of antibodies for 1 h before addition to Huh7.5 cells (a kind gift
from C. Rice, Rockefeller University) and incubation for 72 h at 37°C.
Cells were then fixed and stained for NS5A, and the number of infected
foci was determined by counting immunofluorescence (IF)-positive cells.
The number of infected cells was compared to untreated samples, or to
samples in the presence of control IgG, to calculate the percentage of
inhibition.
RNA transcripts were produced and electroporated into Huh7.5 cells
as previously described (29). A plasmid encoding the E1/E2 primary iso-
late UKN1A20.8 (GenBank accession number EU155192) was used as the
template for the production ofHCVpseudoparticles containingwild-type
(wt) or HVR1 E2, as previously described (30). Infectivity in Huh7 cells
was determined after 48 h by reading the luciferase activity in lysed cells
(Promega).
Peptides and complex formation. A synthetic peptide comprising
residues 412 to 423 (QLINTNGSWHVN) of genotype 1a strain Glasgow
(GenBank accession number AY885238), which differs from the H77 ref-
erence sequence by a V422I substitution (31), was synthesized by the
American Peptide Company (98% purity) and dissolved in water plus
5% dimethyl sulfoxide (DMSO) at 10 mg/ml. A complex containing 1.5
mg/ml peptide plus 9 mg/ml Fab was formed overnight at 293 K.
Crystallization, data collection, structure determination, and re-
finement. Complex crystals were grown at 293 K by using the hanging-
drop vapor diffusion method with drops containing 1 l complex solu-
tion (10.6mg/ml in 10mMTris [pH 8.0], 100mMNaCl)mixed with 1l
reservoir solution. This reservoir solution contained 100 mM Tris (pH
7.5), 27% polyethylene glycol 4000 (PEG 4000), and 100 mM Na-acetate
or 100 mM Tris (pH 8.5) and 66% 2-methyl-2,4-pentanediol (MPD) for
crystals in space group P1 or P21, respectively. Diffraction quality crystals
appeared after 1 week and were flash-frozen in mother liquor with (space
group P1) or without (space group P21) 22% glycerol. Space groups and
cell dimensions of the crystals, the number of complexes per asymmet-
ric unit, resolution limits, data collection details, and refinement sta-
tistics are summarized in Table 2.
Data were collected on the beamline Proxima-1 at Synchrotron Soleil,
processed, scaled, and reduced by using XDS (32), Pointless (33), and
programs from the CCP4 suite (34). The crystal structures of the Fab
complexes were determined by the molecular replacement method using
Phaser (35). We used separate variable and constant regions of a hypo-
thetical Fab fragment assembled from the best sequence match in the
Protein Data Bank (PDB), the light chain (LC) reported under PDB ac-
cession number 1NLD and the heavy chain (HC) reported under PDB
accession number 3EOT, as a search model for the P21 crystals and the
refined P21 structure as a search model for the P1 crystal form. Model
building was performed by using Coot (36), and refinement was done by
using AutoBuster (37).
Crystal structure analysis. The two peptides derived from the differ-
ent crystal forms were superposed by using an iterative alignment process
pruning long atom pairs until no pair exceeded 0.5 Å, implemented in the
MatchMaker algorithm of Chimera (38) and the MultiProt server (39).
Root mean square deviations (RMSDs) between the peptides derived
from different crystal forms of the 3/11 complex were calculated either
over all atoms per residue or by taking into account only the main-chain
atoms (N, CA, C, and O), using Chimera.
Buried solvent-accessible surface areas for the interfaces as well as for
individual residues within the peptides were calculated by using the PISA
server (40). Shape complementarity was calculated by using programs of
the CCP4 suite (34). Interactions were determined by using the Protein
Interactions Calculator (PIC) (41). Figures were prepared with Pymol
(http://www.pymol.org/).
Surface plasmon resonance analysis. Real-time surface plasmon res-
onance (SPR) assays were performed by using a Biacore 2000 instrument
(GE Healthcare) equilibrated at 25°C in phosphate-buffered saline (PBS)
supplemented with 0.1 mg/ml bovine serum albumin (BSA). To deter-
mine the affinity of the peptide for Fabs 3/11 and AP33, these Fab frag-
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ments (in 10mMacetate [pH4.5])were covalently coupled to the carboxy
methyl moieties of CM5 sensorchips by using a Biacore 2000 instrument
and the Amine Coupling kit (GE Healthcare), achieving immobilization
density (Rimmo) values of 3,000 to 5,000 resonance units (RU) (1 RU
equals 1 pg mm	2). We used Fab e137 (40) as a negative control, because
it recognizes an unrelated conformational epitope withinHCVE2. A trip-
licate series of 10 concentrations of peptides (1 to 2,000 nM) was injected
over the Fab surfaces and an empty reference flow cell for 5 min at a flow
rate of 50 l · min	1. After monitoring dissociation for 10 min, the sur-
faces were regenerated by a 30-s wash with 0.1% SDS. To determine the
affinity of native and denatured glycoproteins for the Fab fragments,
monoclonal antibody C23.21 directed against Strep-Tag (in 10 mM ace-
tate [pH 5.5]) was covalently coupled to all 4 flow cells of CM5 sensor-
chips, achieving an Rimmo of 7,500 to 9,000 RU. Subsequently, full-length
or truncated (native or denatured) HCV sE2 of genotype 1a strain H77
was captured via its Strep-Tag to a density of 300 to 400 RU. A series of 10
concentrations of Fabs 3/11 and AP33 (1.5 to 1,500 nM)was injected over
the HCV sE2 surfaces and an unliganded C23.21 reference flow cell for 8
min at a flow rate of 30 l · min	1. After monitoring dissociation for 5
min, the surfaces were regenerated by two 1-min washes with 10 mM
glycine-HCl (pH 2.0) and one wash with 0.1% SDS.
The real-time interaction profiles were double referenced by using
Scrubber 2.0 software (BioLogic Software), i.e., the signals from both
reference surfaces and blank experiments using PBS-BSA instead of pep-
tide or Fab. The association rate (kon), dissociation rate (koff), and the
equilibrium dissociation constant (Kd) were determined by using BIAe-
valuation 4.1 software (GE Healthcare), by globally fitting the processed
experimental curves to a 1:1 Langmuir model. To facilitate direct com-
parisons of the kinetics of binding to different Fab fragments, the binding
response was normalized and expressed as the occupancy of binding sites.
The latter was determined by dividing the experimental SPR signals mea-
sured on each surface by the corresponding maximal binding capacity
(Rmax).
Pulldown assays.To analyze the conformation of sE2 in complexwith
Fab 3/11, UKN2b2.8 sE2 HVR1 was bound to a StrepTactin Superflow
minicolumn, followed by an initial washing step. Subsequently, a 3-fold
molar excess of Fab 3/11 was added, followed by a second washing step
and, afterwards, the addition of a 3-fold molar excess of CBH-4D anti-
body (collection of human material, Institut Pasteur no. DC-2010-1197/
7). After extensive washing, the complex was eluted and analyzed by SDS-
PAGE and Coomassie blue staining.
To determine the interaction of sE2426–717 with conformation-sensi-
tive antibodies and its receptor CD81, sE2426–717 was bound to the col-
umn, followed by an extensive wash step. Subsequently, a 3-fold molar
excess of the large extracellular loop of human CD81 (CD81-LEL) (pro-
duced as described previously [5]), a Fab fragment (e137) (42), or MAb
CBH-4D (43) directed against HCV E2 was added. After extensive wash-
ing, the complex was eluted and analyzed by SDS-PAGE followed by Coo-
massie blue staining.
Protein structure accession numbers. The atomic coordinates and
structure factors for two crystal structures were deposited in the Protein
Data Bank (http://www.pdb.org/) under accession numbers 4WHT and
4WHY.
RESULTS AND DISCUSSION
Crystallization of the Fab-peptide complex and structure deter-
mination. We expressed the Fab fragments derived from MAbs
3/11 and AP33 (the latter one was used as the control throughout
this study) inDrosophila S2 cells. Both Fab fragments were able to
neutralize cell culture-derivedHCV (HCVcc) harboringHCV en-
velope glycoproteins of genotypes 1a (strain H77) and 2a (strain
FIG 1 Neutralization activity of MAbs and Fabs 3/11 and AP33. HCVcc (genotype 1a [H77/JFH] and genotype 2a [J6/JFH {A} or J6/JFH lacking hypervariable
region 1 {J6/JFHHVR1} {B}]) was preincubated with increasing antibody concentrations for 1 h and then used to infect Huh7.5 cells. Cultures were incubated
for 72 h and then methanol fixed, and infection was enumerated by counting NS5A-positive foci by immunofluorescence. Results are presented as means and
standard deviations of data from duplicate (A) or triplicate (B) experiments.
Meola et al.
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J6) in a dose-dependent manner albeit slightly less efficiently than
the parental antibodies, reflecting the reduced avidity of the Fab
fragments (Fig. 1 and Table 1). We performed cocrystallization
trials for a complex containing Fab 3/11 and a peptide comprising
residues 412 to 423 (QLINTNGSWHVN) of genotype 1a strain
Glasgow and obtained diffraction quality crystals in two different
space groups (P1 and P21, respectively) (Table 2). The peptide
sequence used in this study was chosen because it was previously
used for cocrystallization with Fab AP33 (18). The structure of the
Fab 3/11-peptide complex was determined by the molecular re-
placement method (Fig. 2A), using the variable and constant re-
gions of unrelated Fab fragments as separate search models (see
Materials and Methods) in the P21 crystal form. Difference maps
calculated after refinement of the recombinant Fab molecules re-
vealed well-defined electron density for the peptide, which al-
lowed manual building of an atomic model for the peptide (Fig.
3A). The resulting structure of the Fab 3/11-peptide complex is
displayed in Fig. 2A, with Fab 3/11 being almost planar, with an
elbow angle of 171.7°. The peptide conformation is identical in all
complexes in the asymmetric unit (4 and 12 complexes in space
groups P21 and P1, respectively). For further analysis, the peptide
comprising all residues with the lowest mean B value after crystal-
lographic refinement, indicating the highest degree of order in this
part of the structure, from the higher-resolution structure (space
group P1) was selected.
Molecular determinants of the Fab 3/11 interaction with its
peptide epitope. The peptide corresponding to residues 412 to
423 binds to Fab 3/11 in an extended conformation that is deeply
immersed within the cleft between the heavy and light chains (Fig.
2B and C). Clear electron density was observed for all peptide
residues, indicating a highly ordered interface, with a surface area
buried by antigen binding of 871.3 Å2 on the 3/11 paratope (492.3
and 379.0 Å2 on the heavy chain [HC] and light chain [LC], re-
spectively) and a shape complementarity index of 0.78. TheN-ter-
minal part of the peptide interactsmostly with the light chain, and
its C-terminal part makes a right-angle turn around complemen-
tarity-determining region 2 of the heavy chain (CDR-H2). The
central part of the peptide comprising residues N415 to S419 bulges
out, resulting in the side chains of N417 and S419 being exposed
(Fig. 2C). Because the side chain of N423 is also exposed, this over-
all peptide conformation is in line with the fact that N417 and N423
represent N-linked glycosylation sites (44), which, in the context
of the infectious virus particle, need to accommodate the two N-
linked glycans and therefore may not be involved in the antibody
binding face of the epitope (Fig. 4A).
Analysis of the surface area per residue that is buried by Fab
binding confirmed that Q412, L413, W420, and, in particular, N415
are mostly in contact with the light chain, whereas I414, T416, H421,
and V422 interact predominantly with the heavy chain (Fig. 3B).
Analysis of the mean temperature factors (B-factors) per residue
(calculated over the main chain and over all atoms) suggested a
higher degree of disorder at both ends of the peptide (Fig. 3C). The
high B-factor value calculated over all atoms of N417 compared to
its main-chain B-factor value suggests a greater flexibility of the
side chain, in agreement with its role as an attachment site for an
N-linked glycan.
A number of cell culture-adaptive mutations or antibody es-
cape mutants have been identified within this antigenic site, in-
cluding the N415Y (selected with MAb AP33), N415D, T416A,
N417S, G418D, and I422L neutralization-resistant escape mutants.
Of thesemutations,N415D andN417S severely impaired 3/11 bind-
ing (45). For the N415D mutation, this is likely due to an electro-
static repulsion between the negatively charged side chains of the
TABLE 1 IC50 values for Fabs and MAbs 3/11 and AP33
a
Antibody
IC50 (g/ml) (IC50 [nM]) for strain
H77 J6
Fab 3/11 0.43 (8.48) 2.57 (50.65)
MAb 3/11 0.39 (2.6) 1.89 (12.6)
Fab AP33 0.57 (10.98) 0.83 (15.98)
MAb AP33 0.23 (1.53) 1.05 (7)
Control IgG 61.76 (411.73) 107.3 (715.33)
a IC50, 50% inhibitory concentration.
TABLE 2 Data collection and refinement statistics
Parameter
Value for complexa
Fab 3/11
 peptide
reported under PDB
accession no. 4WHY
Fab 3/11
 peptide
reported under PDB
accession no. 4WHT
Data collection statistics
Space group P21 P1
No. of complexes
per AUb
4 12
Cell dimensions
a, b, c (Å) 64.76, 205.51, 69.02 64.79, 128.23, 163.63
, ,  (°) 90, 103.18, 90 88.79, 94.36, 96.15
Resolution range (Å) 50.00–2.62 (2.76–2.62) 48.74–2.22 (2.34–2.22)
Rmerge 0.068 (0.444) 0.072 (0.383)
I/I 9.9 (1.6) 9.0 (1.8)
Completeness (%) 97.0 (87.5) 95.4 (81.4)
Redundancy 3.2 (2.1) 2.4 (1.8)
Refinement statistics
Resolution range (Å) 47.97–2.62 32.50–2.22
No. of reflections 50,781 246,026
Rwork/Rfree 0.204/0.258 0.209/0.243
No. of atoms
Protein 13,022 39,256
Ligand
Water 156 850
No. of residues
per AU
1,710 5,169
Mean temp factors
(B factors)
Protein 59.61 41.72
Ramachandran
statistics (%)
Favored 96.4 97.2
Allowed 3.0 2.5
Outliers 0.6 0.3
RMSD
Bond length (Å) 0.01 0.01
Bond angles (°) 1.25 1.23
a Values in parentheses correspond to the highest-resolution shell.
b AU, asymmetric unit.
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aspartic acid and E31 within the CDR-L1 (EL31). Given that 95%
of the solvent-accessible surface of N415 is buried, the interface
between 3/11 and E2 cannot accommodate bulky amino acids
larger than asparagine at this position, explaining why the N415Y
mutation abolishes virus neutralization by 3/11 (46). The N417S
mutation shifts the N-linked glycosylation site from N417 to N415
(17), where the glycan chain cannot be accommodated within the
interface. These results indicate an antibody-antigen complex in-
terface that is dominated by residues N415, W420, and H421, in line
with data from our previously reported alanine scanning mu-
tagenesis analysis (20), supporting the notion that our structure
reflects the native antibody-antigen interaction.
Conformation of the E2 peptide comprising aa 412 to 423. In
spite of the extended conformation, the bulge at the peptide center
results in the same overall number of backbone hydrogen bonds
found in the -hairpin; however, no similarities between hydro-
gen bonding networks or the corresponding peptide conforma-
tions were observed (Fig. 3). In solution, the peptide is likely to
adopt several different conformations that are in equilibrium, and
different antibodies bind to it according to the principle of con-
formational selection. All four antibodies for which the peptide
structure has been reported (HCV1, AP33, Hu5B3.v3, and 3/11)
neutralize HCV infection (i.e., they bind to their respective
epitopes at the surface of infectious virions), suggesting that the
peptide spanning aa 412 to 423 adopts different conformations.
Our structure therefore illustrates that the previously reported
structural flexibility of HVR1 (8) extends to the downstream neu-
tralizing antigenic site (aa 412 to 423), in line with the recently
reported increased deuterium exchange rate in the context of a
soluble E2 ectodomain (10). The fact that all four antibodies neu-
tralize HCV infection by inhibiting the E2-CD81 interaction (19,
21, 47) suggests that both conformations can be accessible at the
virus surface, likely in a dynamic equilibrium that can be shifted
into either direction by antibody binding. The dose-dependent
neutralization of both MAbs 3/11 and AP33 (98% of HCVcc
H77) (Fig. 1A) supports this hypothesis. Our results suggest that
any of the four antibodies binding to aa 412 to 423 at the virus
surface will contribute to neutralization by shifting the equilib-
rium into the respective direction.
One possible explanation for the observed difference in pep-
tide conformations is that the epitope structure depends on the
polypeptide sequence up- and/or downstream of the antigenic
site, implying that different strains/isolates present the epitope in
different conformations. Evidence for such a strain-specific mod-
ulation of neutralization profiles was reported for a group of
broadly neutralizing humanMAbs targeting aa 412 to 423 (HC33
antibodies) in spite of an identical amino acid sequencewithin this
site (22). It should be noted, however, that NAbs targeting this
antigenic site neutralize a broad range ofHCVgenotypes indepen-
dent of the recognized conformation (19, 20), suggesting that the
isolate-specific amino acid sequences are unlikely to determine
the conformation of the antigenic site spanning aa 412 to 423 but
rather modulate the neutralization efficiency byminor changes in
epitope presentation.
Another possible explanation could be a conformational
change that E2, in particular the antigenic site spanning aa 412 to
423, undergoes during virus entry, suggesting that the two confor-
mations may represent snapshots of the same region at different
FIG 2 Crystal structure of Fab 3/11 in complex with its peptide epitope. (A) The crystal structure of the Fab 3/11-peptide complex was determined and refined
to a 2.2-Å resolution (shown as a cartoon). The peptide (orange) adopts an extended conformation and interacts with the Fab mainly in the cleft between the
heavy (dark gray) and light (light gray) chains. Complementarity-determining regions 1, 2, and 3 are shown in cyan, light cyan, and dark green, respectively, for
the heavy chain and in sand, olive, and yellow, respectively, for the light chain. The peptide N terminus interacts mostly with the light chain, and its C-terminal
part makes a right-angle turn around complementarity-determining region 2 of the heavy chain (CDR-H2). C-terminal residues H421, V422, and N423 interact
exclusively with the heavy chain. (B and C) View on the paratope of the Fab 3/11-peptide complex from two angles illustrating how deeply the peptide immerses
into the cleft between the heavy and light chains. The molecular surface, the peptide, and the complementarity-determining regions of the Fab fragment are
colored as described above for panel A.
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functional stages of the entry process. All four antibodies (HCV1,
AP33, Hu5B3.v3, and 3/11) neutralize HCV infection by interfer-
ing with CD81 binding (19, 21, 47), suggesting that they all neu-
tralize HCV upstream of the E2-CD81 interaction. However, a
more detailed interpretation will require further experiments to
analyzeMAb interactionswith infectious virus particles in a quan-
titative and time-resolved manner (e.g., by precipitation).
Affinity of Fabs 3/11 and AP33 for their epitope peptide and
native soluble E2. To further investigate the role of the distinct
epitope conformations in antigen binding, we determined the
equilibriumdissociation constants (Kd) aswell as association (kon)
and dissociation (koff) rates for the binding of Fabs 3/11 and AP33
to themonomeric full-length E2 ectodomain (wt sE2) and epitope
peptides by surface plasmon resonance (SPR). SPR analysis was
performed by using the crystallized peptide as well as the corre-
sponding peptide derived from the H77 reference strain to allow
direct comparison of peptide and sE2 binding kinetics and re-
vealed no major differences in binding kinetics between the two
peptides, in line with the facts that the V422I substitution is the
only difference between the two peptides and that I422 is not a
major determinant of the Fab binding interface. The affinity of
Fab 3/11 for the H77 peptide was 10-fold higher than that for
sE2 of strain H77 (Kd values of 6.5 nM and 65 nM for the peptide
and sE2, respectively) (Table 3 and Fig. 5), suggesting that the
extended conformation observed in our structure can be adopted
more easily by the peptide than by sE2, likely due to the presence of
the surrounding N- and C-terminal polypeptide chains. Similar
values for glycoprotein-Fab affinity were observed with inversed
SPR settings with the Fab fragment covalently coupled to the sur-
face (data not shown), confirming the obtained kinetic parame-
ters. The relatively slow association and high stability of the com-
plex are in line with the peptide being deeply immersed into the
FIG3 Analysis of the peptide comprising aa 412 to 423. (A) Electron density of a composite omitmap of the Fab 3/11-peptide complex contoured at 1, allowing
for manual building of the peptide model. The peptide is shown as sticks and is colored by atom type (orange, red, and blue for carbon, oxygen, and nitrogen,
respectively). Green arrows indicate asparagine residues N417 and N423 that carry N-linked glycans in the infectious virus particle. (B) Percentages of accessible
surface area (ASA) buried in the complex, calculated by using PISA (40), represented per residue as stacked columns for heavy (dark gray) and light (light gray)
chains of Fab 3/11. (C) Average temperature factor values after crystallographic refinement of the peptide plotted per residue (light gray) and taking into account
only backbone atoms (dark gray) illustrate that only the terminal peptide residues are less ordered, suggesting that they contribute less to antigen binding. In
addition, the side chain of N417, the only really exposed residue, displays a higher temperature factor value. (D and E) The paratope of Fab 3/11 is shown as a
molecular surface, and its peptide epitope is shown as sticks, colored as described above for panel A. The molecular surface of the paratope is colored according
to its electrostatic potential (	5 kT/e [red] to 5 kT/e [blue]) across the molecular surface of the paratope, calculated by using the adaptive Poisson-Boltzmann
solver (D) or according to a normalized hydrophobicity scale from white (hydrophobic) to bright yellow (hydrophilic) (E).
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cleft between the heavy and light chains. Fab AP33 bound the
peptide with a lower affinity than did Fab 3/11 (Kd, 50.9 nM) but
bound wt sE2 with an 2-fold-higher affinity (Kd, 38 nM). The
binding was in both cases characterized by faster association and
dissociation than for Fab 3/11 (Table 3). A closer look at the ki-
netic parameters revealed that Fab 3/11 dissociates more slowly
from its antigen than does Fab AP33, whereas Fab AP33 associates
with its antigen faster than does Fab 3/11 (Fig. 5B and C). One
possible explanation for these differences in kinetic parameters
could be a high prevalence of the -hairpin, compared to the low
prevalence of the extended conformation, although quantitative
binding experiments using Fab and infectious virus particles are
necessary to support this hypothesis. These differences in binding
kinetics may explain the apparent contradiction in previous affin-
ity comparisons of the two antibodies obtained by an enzyme-
linked immunosorbent assay (ELISA)-based method using IgG
(20), which likely detected a higher kon of AP33 than of 3/11 but
failed to account for koff values. Alternatively, the bivalency of the
antibody could compensate for the lower stability of the AP33
complex, whereas it does not affect the lower association rate of
3/11. In summary, we observed similar overall affinities for the
binding of both Fabs to wt sE2, but kinetic binding analysis re-
vealed marked differences in association and dissociation rates.
The kinetic binding parameters together with the 2-fold-
higher neutralization potency of MAb AP33 (Fig. 1A and Table 1)
suggest that the latter is determined mainly by the higher on-rate.
A similar relationship between kinetic binding parameters and
biological activity was reported for affinity-maturated Fab mole-
cules against envelope protein F of respiratory syncytial virus
(RSV), where kon was the crucial kinetic parameter that deter-
mined the biological activity of the IgG molecules, whereas slow
dissociation increased the overall affinity but did not improve the
neutralizing capacity (48, 49). For other antibodies, a direct link
between a lower koff rate and improved biological activity has been
established (50–52), but the correlation is not necessarily linear
(50), and in some cases, only specificity determines the biological
activity, in spite of a low binding affinity (53).
An important role in shielding neutralizing epitopes, in partic-
ular of the CD81 binding site, has been attributed to HVR1 (54,
55). To analyze the contribution of this region to Fab binding and
neutralization, we first determined the kinetic parameters for the
interaction between Fabs 3/11 and AP33 and an E2 ectodomain
lacking HVR1 (encoding H77 aa 412 to 717) (sE2 HVR1). Fab
3/11 bound to the mutant with an affinity similar to that for the
peptide (Kd, 26 nM) andwith a 4-fold-higher association rate than
that for wt sE2, suggesting that the presence of HVR1 restricts Fab
3/11 binding to wt sE2. In contrast, Fab AP33 bound sE2 HVR1
with a 2.5-fold-lower affinity than that for the wt glycoprotein due
to a higher dissociation rate (Table 3 and Fig. 5B and C). These
results suggest that the presence of HVR1, while hampering Fab
3/11 binding to wt sE2, contributed to the stability of the AP33-
glycoprotein complex. This could be due to additional contact
residues or a direct stabilizing effect of HVR1 on the -hairpin.
MAbs and patient sera targeting the CD81 binding site within
E2neutralizeHVR1HCVccmore efficiently than they neutralize
wt virus (54). Surprisingly, the neutralizing activities of Fab 3/11,
but not that of MAb 3/11, were almost identical for both wt and
HVR1 viruses (Fig. 1B), despite the faster association with sE2
HVR1. Similarly, while both Fab AP33 and MAb AP33 neutral-
ized HVR1 virus more efficiently than they neutralized wt virus
(Fig. 1B), this difference was more pronounced for MAb AP33
(9-fold) than for the Fab fragment (2-fold). These results sug-
gest that, independent of the kinetic binding parameters, bivalent
IgG molecules neutralize HVR1 virus more efficiently than do
FIG 4 Relevant conformations of the antigenic site spanning aa 412 to 423.
(A) Compatibility of the Fab 3/11-peptide complex structure with the position
of N-linked glycans attached to N417 and N423 of the native glycoprotein.
Shown is a cartoon representation of the peptide, ramp colored from blue to
red through yellow, from the N to the C termini, with the two asparagine side
chains shown as sticks and the ND2 atoms, to which the sugar chains are
linked, shown in blue. Hypothetical glycan chains containing two N-acetylg-
lucosamine moieties and one mannose moiety (light orange) are modeled to
visualize the extended conformation of the native glycoprotein required for
3/11 binding. (B and C) Comparison of both peptide conformations observed
for aa 412 to 423. The backbone atoms of the peptides bound to Fab 3/11 (B)
and Fab HCV1 (C) (15), as an example of the -hairpin conformation of aa
412 to 423, are shown as sticks and colored by atom type (green, red, and blue
for carbon, oxygen, and nitrogen, respectively) to illustrate the differences in
the backbone conformations observed for the two structures. The five hydro-
gen bonds stabilizing the backbone conformation in both structures are indi-
cated as dotted lines.
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the corresponding monovalent Fab molecules, whereas for wt vi-
rus, this appears to depend on the particular NAb. Of note, corre-
sponding IgG and Fab molecules do not necessarily utilize
identical neutralization mechanisms (56). In summary, our re-
sults support a model in which the removal of HVR1 results in
increased exposure of the CD81 binding site, an effect that is likely
to bemore pronounced for largerMAbs (molecularmass of150
kDa) than for smaller Fab molecules (molecular mass of 50
kDa).
Requirement of aa 412 to 423 for protein folding and infec-
tivity. The very low RMSD of 0.8 Å between C atoms of the two
E2 core fragments, one containing and one lacking the 44 residues
downstream of HVR1 (aa 412 to 456) (10, 11), indicates that this
region is not required for E2 folding and therefore that the binding
of MAb 3/11 is unlikely to affect the overall fold of E2. To test this
hypothesis, we determined the binding of the conformation-sen-
sitive, nonneutralizing human antibody CBH-4D (43) to a Fab
3/11-sE2 HVR1 complex by a coprecipitation assay. SDS-PAGE
analysis of the eluted fractions demonstrated that sE2 HVR1 in
complex with Fab 3/11 efficiently bound the CBH-4D antibody
(Fig. 6A), indicating that 3/11 binding does not affect the overall
fold of the glycoprotein.
TABLE 3 Kinetic parameters of Fab 3/11 and AP33 binding to peptide and sE2
Affinity kon (M
	1 · s	1) SE koff (s
	1) SE Kd (nM) (SE)
“Glasgow” peptide over:
Fab AP33a,b 5.9 105 0.5 105 3.1 10	2 0.2 10	2 55.3 (3.6)
Fab 3/11a,b 4.6 105 0.4 105 3.6 10	3 0.3 10	3 7.9 (0.7)
“H77” peptide over:
Fab AP33a,b 5.1 105 0.3 105 2.5 10	2 0.1 10	2 50.9 (3.3)
Fab 3/11a,b 3.9 105 0.2 105 2.6 10	3 0.2 10	3 6.5 (0.4)
Fab 3/11 over:
sE2b 4.1 103 2.7 10	4 65
sE2 HVR1b 15 103 4.1 10	4 26
Denatured sE2 HVR1b 11 103 5.0 10	4 44
Fab AP33 over:
sE2b 35 103 13 10	4 38
sE2 HVR1b 45 103 43 10	4 97
Denatured sE2 HVR1b 29 103 57 10	4 196
a Fab affinities for the peptide were determined in three independent experiments and are shown as mean values with standard errors.
b koff values were determined by globally fitting dissociation profiles alone, while kon and Kd values were determined by globally fitting association and dissociation profiles
simultaneously.
FIG 5 SPR analysis of Fab binding to aa 412 to 423. To facilitate direct comparisons of the kinetics of binding to different Fab fragments, the binding response
was normalized in each case, as described inMaterials andMethods, and expressed as the occupancy of binding sites. (A) Real-time SPR analysis of the interaction
of the epitope peptides derived from genotype 1a strain Glasgow and H77 with immobilized Fab fragments. The respective epitope peptide was injected over a
surface of covalently immobilized Fab at a flow rate of 50 l/ml, and the binding response in resonance units (RU) was recorded as a function of time. To
compensate for the small signal (due to the lowmolecular mass of the peptide ligand of2 kDa), three independent experiments were performed, and themean
values with standard errors are presented in Table 3. The representative association/dissociation time course profile shown corresponds to an injection of 125 nM
peptide over each of the Fabs, illustrating the different kinetic properties of the two Fab-peptide complexes. (B and C) Real-time SPR analysis of the binding of
FabsAP33 (B) and 3/11 (C) to the immobilizedHCVE2 ectodomain. Fabswere injected overHCV sE2 immobilized by using an anti-Strep-Tag antibody at a flow
rate of 30 l/ml, and the binding response in RU was recorded as a function of time. Representative association/dissociation time course profiles correspond to
the injection of Fabs (355 nM) over full-length immobilized HCV sE2 or native and denatured HCV sE2 HVR1.
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Deletion of the N-terminal 72 residues of E2 abolishes binding
to its cellular receptor CD81 (10), whereas deletion of HVR1 does
not affect CD81 binding (7). To analyze the role of aa 412 to 423,
we expressed recombinant soluble E2 lacking the N-terminal 42
residues (encoding aa 426 to 717) (sE2426–717). As anticipated, size
exclusion chromatography (SEC) analysis revealed a majority of
the purified protein eluting at a volume corresponding to amono-
mer, confirming that the deletion of aa 412 to 425 does not lead to
multimer formation via nonproper interchain disulfides and
therefore likely does not impair protein folding (Fig. 6B). To an-
alyze the adopted conformation of the deletion mutant, we used
pulldown assays to analyze the interaction of sE2426–717 with the
soluble portion of CD81 (CD81-LEL) and Fab fragments derived
from nonoverlapping conformation-sensitive human MAbs
(CBH-4D and e137), one derived from a broadly neutralizing an-
tibody overlapping the CD81 binding site (e137) (42) and one
derived from a nonneutralizing antibody (CBH-4D). As expected,
Fab CBH-4D bound sE2426–717, but no interaction between
sE2426–717 and Fab e137 or CD81-LEL was observed (Fig. 6C),
suggesting that sE2426–717 adopts a native overall fold but that the
binding capacity of its CD81 binding site is impaired.
The role of aa 412 to 425 in the viral cycle was further investi-
gated by using retroviral particles pseudotyped with envelope
glycoproteins (HCVpp) derived from primary HCV isolate
UKN1A20.8 lacking the region encompassing aa 384 to 425.
HCVpp carrying glycoproteins from this isolate were shown to be
highly infectious (20). HCVpp infectivity was ablated by the
E2aa384–425 mutant (Fig. 6D), in spite of the incorporation of E2
FIG6 Effect of deletion of aa 412 to 425 on protein folding and infectivity. (A) Pulldown assay of the conformation-dependent nonneutralizing human antibody
CBH-4D (43) by sE2 HVR1 and the Fab 3/11-sE2 HVR1 complex indicating that Fab 3/11 binding does not affect the overall glycoprotein fold. (B) Elution
profile of sE2426–717 (UKN2B2.8) from a Superdex200 size exclusion column. AU, absorption units. (C) Pulldown assay of CD81-LEL, Fab CBH-4D, and Fab
e137 by sE2426–717 reveals an intact overall glycoprotein fold but severely impaired binding to the CD81 binding site. (D to G) Infectivity of deletion mutants in
HCVcc and HCVpp models of infection. (D) The E1/E2 genes of the highly infectious primary isolate UKN1A20.8 were used as the template for the deletion of
amino acids 384 to 425. HCVpp possessing wt and mutant glycoproteins were used to infect Huh7 cells. Infectivity measurements were performed with a
luciferase reporter gene. Only target cells inoculated with wild-type HCVpp exhibited luciferase activity. RLU, relative light units. (E, top)Western blot analysis
of HCVpp using the linear anti-E2 MAb ALP98 reveals similar E2 incorporation levels for wt and mutant HCVpp (lanes 1 and 2, respectively). (Bottom) The
amount of particles was verified by Western blotting using an anti-Gag antibody. (F and G) A plasmid encoding a chimeric J6/JFH-1 virus was used as the
template for the deletion of amino acids 384 to 425. RNA transcripts of wt and mutant viruses were electroporated into Huh7.5 cells. Results are presented as
means and standard deviations from duplicate experiments. (F) RNA replication was assessed by intracellular staining for the presence of HCV NS5a in
electroporated cells. Both constructs replicated similarly, with the deletion mutant having slightly enhanced replication. (G) Cell supernatants harvested 24, 48,
and 72 h after transfection were assessed for the presence of infectious virus by infecting naive Huh7.5 cells. Infectious wild-type virus was produced, while no
infectivity was observed for the mutant virus.
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into purified HCVpp (Fig. 6E), suggesting that the deletion of aa
384 to 425 affected the entry of retroviral pseudoparticles, which is
in line with impaired CD81 binding. Since HCVpp have been
shown to be more sensitive to glycoprotein mutations than
HCVcc (45), we introduced the same deletion into an infectious
HCVcc chimera (J6/JFH1). Despite clear evidence of intracellular
replication of the virus genome (Fig. 6F), no infectious particles
were released from cells transfected with the mutant genome
(Fig. 6G). These results confirm the essential role of the antigenic
site comprising aa 412 to 423 during HCV entry.
Concluding remarks. In summary, the striking structural flex-
ibility displayed by the antigenic site at aa 412 to 423 confirms that
this region of E2 is not part of a structured domain. As described
above, the glycan chain attached toN417 requires the peptide chain
to adopt an extended conformation to allow binding ofMAb 3/11.
The neutralizing activity of MAb 3/11 indicates that this extended
conformation is present at the surface of infectious particles dur-
ing virus entry and that the N-terminal 40 residues within E2 are
structurally flexible. This is in agreement with the recently ob-
served elevated deuterium exchange rates for the N-terminal 72
residues within E2 (10) and with the finding that the reported
conformation of the E2 ectodomain core front layer (correspond-
ing to aa 412 to 491) is likely to be partially induced byMAbAR3C
binding (11).
The structural flexibility of this antigenic site is likely to con-
tribute to its reduced immunogenicity in patients (22, 25). Hu-
man immunodeficiency virus (HIV) has been reported to utilize
conformational flexibility in the CD4 binding site within the en-
velope protein gp120 as an immune evasion mechanism (re-
viewed in reference 57). For NAbs targeting the protruding (P)
domain of the capsid ofmurine norovirus type 1 (MNV-1), escape
mutants were shown to switch conformations in the two structur-
ally flexible P domain loops, resulting in a deterioration of the
stereochemical fit of the NAb paratope to the P domain (58). It is
tempting to speculate that HCV also employs structural flexibility
as an immune evasion mechanism to prevent NAbs targeting this
conserved receptor binding domain from being elicited. While
our structural analysis suggests that the antigenic site spanning aa
412 to 423 can adopt at least two different conformations, the
majority of monoclonal antibodies characterized so far recognize
the -hairpin. In addition, our SPR analysis highlights differences
in the kinetic behaviors of MAbs 3/11 and AP33 binding wt sE2
and sE2HVR1, respectively, suggesting that the-hairpinmight
be the predominant conformation that could be stabilized by in-
teractions within E2 and/or E1 at the virus surface. Our data have
implications for vaccine design, because the flexibility in this an-
tigenic site could prevent this epitope from being an ideal candi-
date for an efficient vaccine. In view of a number of potent broadly
neutralizing antibodies directed against different regions within
E2 (23, 42, 59–62), other antigenic sites could potentially be more
advantageous for vaccine design. Our results provide insights into
the recognition of E2 by broadly neutralizing antibodies and are
an important step on the way to developing an efficient vaccine
against HCV.
ACKNOWLEDGMENTS
Thisworkwas funded by theCNRS, anANRS grant and recurrent funding
from the Institut Pasteur to F.A.R., and an ANRS grant to T.K.
We thank Ahmed Haouz and Patrick Weber from the crystallization
platform for help in crystallization, Richard Urbanowicz for help with
initial experiments and valuable discussions, and staff of the synchrotron
beamline Proxima-1 at Synchrotron Soleil for help during data collection.
REFERENCES
1. Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis
C virus infection. Lancet Infect Dis 5:558–567. http://dx.doi.org/10.1016
/S1473-3099(05)70216-4.
2. Schinazi R, Halfon P, Marcellin P, Asselah T. 2014. HCV direct-acting
antiviral agents: the best interferon-free combinations. Liver Int 34(Suppl
1):S69–S78. http://dx.doi.org/10.1111/liv.12423.
3. Ball JK, Tarr AW, McKeating JA. 2014. The past, present and future of
neutralizing antibodies for hepatitis C virus. Antiviral Res 105:100–111.
http://dx.doi.org/10.1016/j.antiviral.2014.02.013.
4. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R,
Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. 1998. Binding
of hepatitis C virus to CD81. Science 282:938–941. http://dx.doi.org/10
.1126/science.282.5390.938.
5. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G,
Traboni C, Nicosia A, Cortese R, Vitelli A. 2002. The human scavenger
receptor class B type I is a novel candidate receptor for the hepatitis C
virus. EMBO J 21:5017–5025. http://dx.doi.org/10.1093/emboj/cdf529.
6. Kato N, Ootsuyama Y, Ohkoshi S, Nakazawa T, Sekiya H, Hijikata M,
Shimotohno K. 1992. Characterization of hypervariable regions in the
putative envelope protein of hepatitis C virus. BiochemBiophys ResCom-
mun 189:119–127. http://dx.doi.org/10.1016/0006-291X(92)91533-V.
7. McCaffrey K, Boo I, Poumbourios P, Drummer HE. 2007. Expression
and characterization of a minimal hepatitis C virus glycoprotein E2 core
domain that retains CD81 binding. J Virol 81:9584–9590. http://dx.doi
.org/10.1128/JVI.02782-06.
8. Taniguchi S, Okamoto H, Sakamoto M, Kojima M, Tsuda F, Tanaka T,
Munekata E, Muchmore EE, Peterson DA, Mishiro S. 1993. A structur-
ally flexible and antigenically variable N-terminal domain of the hepatitis
C virus E2/NS1 protein: implication for an escape from antibody. Virol-
ogy 195:297–301. http://dx.doi.org/10.1006/viro.1993.1378.
9. Forns X, Thimme R, Govindarajan S, Emerson SU, Purcell RH, Chisari
FV, Bukh J. 2000. Hepatitis C virus lacking the hypervariable region 1 of
the second envelope protein is infectious and causes acute resolving or
persistent infection in chimpanzees. Proc Natl Acad Sci U S A 97:13318–
13323. http://dx.doi.org/10.1073/pnas.230453597.
10. Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV,
Cygan A, Price AA, Yost SA, Bohannon CD, Jacob J, Grakoui A,
Marcotrigiano J. 2014. Structure of the core ectodomain of the hepa-
titis C virus envelope glycoprotein 2. Nature 509:381–384. http://dx
.doi.org/10.1038/nature13117.
11. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, Dai X,
Stanfield RL, Burton DR, Ward AB, Wilson IA, Law M. 2013. Hepatitis
C virus E2 envelope glycoprotein core structure. Science 342:1090–1094.
http://dx.doi.org/10.1126/science.1243876.
12. Deng L, Zhong L, Struble E, Duan H, Ma L, Harman C, Yan H,
Virata-Theimer ML, Zhao Z, Feinstone S, Alter H, Zhang P. 2013.
Structural evidence for a bifurcated mode of action in the antibody-
mediated neutralization of hepatitis C virus. Proc Natl Acad Sci U S A
110:7418–7422. http://dx.doi.org/10.1073/pnas.1305306110.
13. Deng L, Ma L, Virata-Theimer ML, Zhong L, Yan H, Zhao Z, Struble
E, Feinstone S, Alter H, Zhang P. 2014. Discrete conformations of
epitope II on the hepatitis C virus E2 protein for antibody-mediated neu-
tralization and nonneutralization. Proc Natl Acad Sci U S A 111:10690–
10695. http://dx.doi.org/10.1073/pnas.1411317111.
14. Kong L, Giang E, Nieusma T, Robbins JB, Deller MC, Stanfield RL,
Wilson IA, Law M. 2012. Structure of hepatitis C virus envelope glyco-
protein E2 antigenic site 412 to 423 in complex with antibody AP33. J
Virol 86:13085–13088. http://dx.doi.org/10.1128/JVI.01939-12.
15. Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, Law
M. 2012. Structural basis of hepatitis C virus neutralization by broadly
neutralizing antibody HCV1. Proc Natl Acad Sci U S A 109:9499–9504.
http://dx.doi.org/10.1073/pnas.1202924109.
16. Krey T, Meola A, Keck Z-Y, Damier-Piolle L, Foung SKH, Rey FA.
2013. Structural basis of HCV neutralization by humanmonoclonal anti-
bodies resistant to viral neutralization escape. PLoS Pathog 9:e1003364.
http://dx.doi.org/10.1371/journal.ppat.1003364.
17. Pantua H, Diao J, Ultsch M, Hazen M, Mathieu M, McCutcheon K,
Takeda K, Date S, Cheung TK, Phung Q, Hass P, Arnott D, Hongo J-A,
Structurally Flexible HCV E2 Neutralizing Epitope
February 2015 Volume 89 Number 4 jvi.asm.org 2179Journal of Virology
 o
n
 January 26, 2016 by University of Birm
ingham
http://jvi.asm.org/
D
ow
nloaded from
 
Matthews DJ, Brown A, Patel AH, Kelley RF, Eigenbrot C, Kapadia SB.
2013. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a
mechanism for escape from broadly neutralizing antibodies. J Mol Biol
425:1899–1914. http://dx.doi.org/10.1016/j.jmb.2013.02.025.
18. Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck Z-Y, Lau P,
Foung SKH, Taylor GL, Patel AH. 2012. Toward a hepatitis C virus
vaccine: the structural basis of hepatitis C virus neutralization by AP33, a
broadly neutralizing antibody. J Virol 86:12923–12932. http://dx.doi.org
/10.1128/JVI.02052-12.
19. Broering TJ, Garrity KA, Boatright NK, Sloan SE, Sandor F, Thomas
WD, Szabo G, Finberg RW, Ambrosino DM, Babcock GJ. 2009. Iden-
tification and characterization of broadly neutralizing humanmonoclonal
antibodies directed against the E2 envelope glycoprotein of hepatitis C
virus. J Virol 83:12473–12482. http://dx.doi.org/10.1128/JVI.01138-09.
20. Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJP, Hick-
ling TP, Pietschmann T, Bartenschlager R, Patel AH, Ball JK. 2006.
Characterization of the hepatitis C virus E2 epitope defined by the broadly
neutralizing monoclonal antibody AP33. Hepatology 43:592–601. http:
//dx.doi.org/10.1002/hep.21088.
21. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk
P, Higginbottom A, Levy S, McKeating JA. 1999. Characterization of
hepatitis C virus E2 glycoprotein interaction with a putative cellular re-
ceptor, CD81. J Virol 73:6235–6244.
22. Keck Z, Wang W, Wang Y, Lau P, Carlsen TH, Prentoe J, Xia J, Patel
AH, Bukh J, Foung SK. 2013. Cooperativity in virus neutralization by
human monoclonal antibodies to two adjacent regions located at the
amino terminus of hepatitis C virus E2 glycoprotein. J Virol 87:37–51.
http://dx.doi.org/10.1128/JVI.01941-12.
23. Sabo MC, Luca VC, Prentoe JC, Hopcraft SE, Blight KJ, Yi M, Lemon
SM, Ball JK, Bukh J, Evans MJ, Fremont DH, Diamond MS. 2011.
Neutralizing monoclonal antibodies against hepatitis C virus E2 protein
bind discontinuous epitopes and inhibit infection at a postattachment
step. J Virol 85:7005–7019. http://dx.doi.org/10.1128/JVI.00586-11.
24. Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, Szwejk A,
Bienkowska-Szewczyk K, Thomson BJ, Patel AH, Ball JK. 2006. Iden-
tification of conserved residues in the E2 envelope glycoprotein of the
hepatitis C virus that are critical for CD81 binding. J Virol 80:8695–8704.
http://dx.doi.org/10.1128/JVI.00271-06.
25. Tarr AW, Owsianka AM, Jayaraj D, Brown RJP, Hickling TP, Irving
WL, Patel AH, Ball JK. 2007. Determination of the human antibody
response to the epitope defined by the hepatitis C virus-neutralizing
monoclonal antibody AP33. J Gen Virol 88:2991–3001. http://dx.doi.org
/10.1099/vir.0.83065-0.
26. Backovic M, Johansson DX, Klupp BG, Mettenleiter TC, Persson MAA,
Rey FA. 2010. Efficient method for production of high yields of Fab
fragments in Drosophila S2 cells. Protein Eng Des Sel 23:169–174. http:
//dx.doi.org/10.1093/protein/gzp088.
27. Krey T, d’Alayer J, Kikuti CM, Saulnier A, Damier-Piolle L, Petitpas I,
Johansson DX, Tawar RG, Baron B, Robert B, England P, Persson MA,
Martin A, Rey FA. 2010. The disulfide bonds in glycoprotein E2 of hep-
atitis C virus reveal the tertiary organization of themolecule. PLoS Pathog
6:e1000762. http://dx.doi.org/10.1371/journal.ppat.1000762.
28. Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA,
Meola A, Jestin J-L, Brown RJP, McKeating JA, Rey FA, Ball JK, Krey
T. 2013. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-
cell transmission. Hepatology 58:932–939. http://dx.doi.org/10.1002/hep
.26430.
29. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu
CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM.
2005. Complete replication of hepatitis C virus in cell culture. Science
309:623–626. http://dx.doi.org/10.1126/science.1114016.
30. Tarr AW, Urbanowicz RA, Hamed MR, Albecka A, McClure CP,
Brown RJ, Irving WL, Dubuisson J, Ball JK. 2011. Hepatitis C
patient-derived glycoproteins exhibit marked differences in suscepti-
bility to serum neutralizing antibodies: genetic subtype defines anti-
genic but not neutralization serotype. J Virol 85:4246–4257. http://dx
.doi.org/10.1128/JVI.01332-10.
31. Patel AH, Wood J, Penin F, Dubuisson J, McKeating JA. 2000. Con-
struction and characterization of chimeric hepatitis C virus E2 glycopro-
teins: analysis of regions critical for glycoprotein aggregation and CD81
binding. J Gen Virol 81:2873–2883.
32. Kabsch W. 1988. Automatic indexing of rotation diffraction patterns. J
Appl Crystallogr 21:67–72.
33. Evans P. 2006. Scaling and assessment of data quality. Acta Crystallogr
D Biol Crystallogr 62:72–82. http://dx.doi.org/10.1107/S090744490
5036693.
34. Collaborative Computational Project. 1994. The CCP4 suite: programs
for protein crystallography. Acta Crystallogr D Biol Crystallogr 50:760–
763. http://dx.doi.org/10.1107/S0907444994003112.
35. McCoy LE, Quigley AF, Strokappe NM, Bulmer-Thomas B, Seaman
MS, Mortier D, Rutten L, Chander N, Edwards CJ, Ketteler R, Davis D,
Verrips T, Weiss RA. 2012. Potent and broad neutralization of HIV-1 by
a llama antibody elicited by immunization. J Exp Med 209:1091–1103.
http://dx.doi.org/10.1084/jem.20112655.
36. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and devel-
opment of Coot. Acta Crystallogr D Biol Crystallogr 66:486–501. http:
//dx.doi.org/10.1107/S0907444910007493.
37. Bricogne G, Blanc E, Brandl M, Flensburg C, Keller P, Paciorek P,
Roversi P, Sharff A, Smart O, Vonrhein C, Womack T. 2010. BUSTER
version 2.9. Global Phasing Ltd, Cambridge, United Kingdom.
38. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM,
Meng EC, Ferrin TE. 2004. UCSF Chimera—a visualization system for
exploratory research and analysis. J Comput Chem 25:1605–1612. http:
//dx.doi.org/10.1002/jcc.20084.
39. Shatsky M, Nussinov R, Wolfson HJ. 2004. A method for simultaneous
alignment of multiple protein structures. Proteins 56:143–156. http://dx
.doi.org/10.1002/prot.10628.
40. Krissinel E, Henrick K. 2007. Inference of macromolecular assemblies
from crystalline state. J Mol Biol 372:774–797. http://dx.doi.org/10.1016
/j.jmb.2007.05.022.
41. Tina KG, Bhadra R, Srinivasan N. 2007. PIC: Protein Interactions Cal-
culator. Nucleic Acids Res 35:W473–W476. http://dx.doi.org/10.1093/nar
/gkm423.
42. Perotti M, Mancini N, Diotti R, Tarr AW, Ball JK, Owsianka A, Adair
R, Patel AH, Clementi M, Burioni R. 2008. Identification of a broadly
cross-reacting and neutralizing human monoclonal antibody directed
against the hepatitis C virus E2 protein. J Virol 82:1047. http://dx.doi.org
/10.1128/JVI.01986-07.
43. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P,
Abrignani S, Foung SK. 2000. Humanmonoclonal antibodies that inhibit
binding of hepatitis C virus E2 protein to CD81 and recognize conserved
conformational epitopes. J Virol 74:10407–10416. http://dx.doi.org/10
.1128/JVI.74.22.10407-10416.2000.
44. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset F-L, Montpel-
lier C, Dubuisson J. 2005. Role of N-linked glycans in the functions of
hepatitis C virus envelope glycoproteins. J Virol 79:8400–8409. http://dx
.doi.org/10.1128/JVI.79.13.8400-8409.2005.
45. Dhillon S, Witteveldt J, Gatherer D, Owsianka AM, Zeisel MB, Zahid
MN, Rychłowska M, Foung SKH, Baumert TF, Angus AGN, Patel AH.
2010. Mutations within a conserved region of the hepatitis C virus E2
glycoprotein that influence virus-receptor interactions and sensitivity to
neutralizing antibodies. J Virol 84:5494–5507. http://dx.doi.org/10.1128
/JVI.02153-09.
46. Gal-Tanamy M, Keck Z-Y, Yi M, McKeating JA, Patel AH, Foung SKH,
Lemon SM. 2008. In vitro selection of a neutralization-resistant hepatitis
C virus escape mutant. Proc Natl Acad Sci U S A 105:19450–19455. http:
//dx.doi.org/10.1073/pnas.0809879105.
47. Owsianka AM, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH.
2001. Functional analysis of hepatitis C virus E2 glycoproteins and virus-
like particles reveals structural dissimilarities between different forms of
E2. J Gen Virol 82:1877–1883.
48. Wu H, Pfarr DS, Tang Y, An L-L, Patel NK, Watkins JD, Huse WD,
Kiener PA, Young JF. 2005. Ultra-potent antibodies against respiratory
syncytial virus: effects of binding kinetics and binding valence on viral
neutralization. J Mol Biol 350:126–144. http://dx.doi.org/10.1016/j.jmb
.2005.04.049.
49. Bates JT, Keefer CJ, Utley TJ, Correia BE, Schief WR, Crowe JE. 2013.
Reversion of somatic mutations of the respiratory syncytial virus-specific
human monoclonal antibody Fab19 reveal a direct relationship between
association rate and neutralizing potency. J Immunol 190:3732–3739.
http://dx.doi.org/10.4049/jimmunol.1202964.
50. Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks
JD, Foung SK. 2011. Affinity maturation to improve human mono-
clonal antibody neutralization potency and breadth against hepatitis C
virus. J Biol Chem 286:44218–44233. http://dx.doi.org/10.1074/jbc
.M111.290783.
Meola et al.
2180 jvi.asm.org February 2015 Volume 89 Number 4Journal of Virology
 o
n
 January 26, 2016 by University of Birm
ingham
http://jvi.asm.org/
D
ow
nloaded from
 
51. VanCott TC, Bethke FR, Polonis VR, Gorny MK, Zolla-Pazner S,
Redfield RR, Birx DL. 1994. Dissociation rate of antibody-gp120 binding
interactions is predictive of V3-mediated neutralization of HIV-1. J Im-
munol 153:449–459.
52. Rani M, Bolles M, Donaldson EF, Van Blarcom T, Baric R, Iverson B,
Georgiou G. 2012. Increased antibody affinity confers broad in vitro pro-
tection against escapemutants of severe acute respiratory syndrome coro-
navirus. J Virol 86:9113–9121. http://dx.doi.org/10.1128/JVI.00233-12.
53. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS,
Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T,
Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD,
Mascola JR, Connors M. 2012. Broad and potent neutralization of HIV-1
by a gp41-specific human antibody. Nature 491:406–412. http://dx.doi
.org/10.1038/nature11544.
54. Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M,
Herrmann E, Zeisel MB, Baumert TF, Keck Z-Y, Foung SKH, Pécheur
E-I, Pietschmann T. 2010. Hepatitis C virus hypervariable region 1 mod-
ulates receptor interactions, conceals the CD81 binding site, and protects
conserved neutralizing epitopes. J Virol 84:5751–5763. http://dx.doi.org
/10.1128/JVI.02200-09.
55. Prentoe J, Jensen TB, Meuleman P, Serre SBN, Scheel TKH, Leroux-
Roels G, Gottwein JM, Bukh J. 2011. Hypervariable region 1 differen-
tially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and
impairs virus neutralization. J Virol 85:2224–2234. http://dx.doi.org/10
.1128/JVI.01594-10.
56. Klasse PJ, Sattentau QJ. 2002. Occupancy and mechanism in antibody-
mediated neutralization of animal viruses. J Gen Virol 83:2091–2108.
57. Pantophlet R, Burton DR. 2006. GP120: target for neutralizing HIV-1
antibodies. Annu Rev Immunol 24:739–769. http://dx.doi.org/10.1146
/annurev.immunol.24.021605.090557.
58. Kolawole AO, Li M, Xia C, Fischer AE, Giacobbi NS, Rippinger CM,
Proescher JB, Wu SK, Bessling SL, Gamez M, Yu C, Zhang R, Mehoke
TS, Pipas JM, Wolfe JT, Lin JS, Feldman AB, Smith TJ, Wobus CE.
2014. Flexibility in surface-exposed loops in a virus capsidmediates escape
from antibody neutralization. J Virol 88:4543–4557. http://dx.doi.org/10
.1128/JVI.03685-13.
59. Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuisson J,
PerssonMAA. 2007. Human combinatorial libraries yield rare antibodies
that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A 104:
16269–16274. http://dx.doi.org/10.1073/pnas.0705522104.
60. Keck Z, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen TH, Li
AY-J, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SK. 2012.
Human monoclonal antibodies to a novel cluster of conformational
epitopes on HCV E2 with resistance to neutralization escape in a ge-
notype 2a isolate. PLoS Pathog 8:e1002653. http://dx.doi.org/10.1371
/journal.ppat.1002653.
61. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gasta-
minza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Knete-
man NM, Burton DR. 2008. Broadly neutralizing antibodies protect
against hepatitis C virus quasispecies challenge. Nat Med 14:25–27. http:
//dx.doi.org/10.1038/nm1698.
62. Keck Z-Y, Olson O, Gal-Tanamy M, Xia J, Patel AH, Dreux M, Cosset
F-L, Lemon SM, Foung SKH. 2008. A point mutation leading to hepatitis
C virus escape from neutralization by a monoclonal antibody to a con-
served conformational epitope. J Virol 82:6067–6072. http://dx.doi.org
/10.1128/JVI.00252-08.
63. Johansson DX, Krey T, Andersson O. 2012. Production of recombinant
antibodies in Drosophila melanogaster S2 cells. Methods Mol Biol 907:
359–370. http://dx.doi.org/10.1007/978-1-61779-974-7_21.
Structurally Flexible HCV E2 Neutralizing Epitope
February 2015 Volume 89 Number 4 jvi.asm.org 2181Journal of Virology
 o
n
 January 26, 2016 by University of Birm
ingham
http://jvi.asm.org/
D
ow
nloaded from
 
